<DOC>
	<DOCNO>NCT02783794</DOCNO>
	<brief_summary>The purpose study determine whether BP-C1 effective treatment metastatic breast cancer patient previously receive least three line chemotherapy .</brief_summary>
	<brief_title>BP-C1 Monotherapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>BP-C1 , solution injection 0.05 % , currently develop treatment patient metastatic breast cancer palliative intent . Active substance product , novel platinum-containing anticancer agent develop intramuscular administration , cis-coordinated complex platinum ( II ) polymer benzene polycarboxylic acid derive lignin ( CDBPA ) . The product complex cis-diammineplatinum ( II ) derive core amphiphilic polymer , contain composition benzene polycarboxylic acid . The amphiphilic characteristic polymer result product clear significantly alter improved property compare platinum analogue , e.g . cisplatin , carboplatin oxaliplatin . BP-C1 preserve antitumour activity predecessor ( e.g . cisplatin carboplatin ) , additionally offer follow advantage ensure favourable outcome treatment metastatic breast cancer patient : - injectable solution ( intramuscular ) cause injection site reaction ; - administer home nurse patient ; - improve pharmacokinetic profile ; - demonstrate efficacy comparable cisplatin much high carboplatin ( in-vitro ; in-vivo data ) ; - exert additional immunomodulatory activity . This study randomise , double-blind , placebo-controlled , multicentre , phase IIb study . The eligible patient allocate ( 1:1 ) either BP-C1 arm Placebo arm treat daily 32 day . The patient allocate Placebo arm cross BP-C1 treatment 32 day progression cancer document late 32-day treatment Placebo . After 32-day treatment BP-C1 patient invite participate study BMC2011-02 continue BP-C1 treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female patient histologically verify metastatic breast cancer ( stage IV ) measurable metastasis , 18 80 year age , undergone least three line chemotherapy expect survival time least 3 month . Exclusion criterion : Patients fulfil least one follow criterion exclude participation study : Abnormal liver function classify total bilirubin &gt; 34 μmol/L ALAT &gt; 3 time upper limit normal ( ULN ) . In case metastasis liver , ALAT limit exclusion set 5хULN . Abnormal kidney function define serum creatinine &gt; 120 μmol/L . Abnormal coagulation capacity define relative arbitrary concentration coagulation factor 2,7,10 ; INR &gt; 1.5 . Verified metastasis brain . Synchronous cancer except nonmelanoma skin cancer early stage cervical cancer . Abnormal hematology status define hemoglobin &lt; 9.0 g/dL , platelet count &lt; 100,000/mm^3 leucocyte &lt; 3 x 10^9/L . Clinically significant abnormal ECG . Karnofsky performance status score &lt; 60 % . Pregnant breast feed woman . Women fertile age want test possible pregnancy . Fertile female want use safe protection pregnancy , start one month start study treatment last least six week . Uncontrolled bacterial , viral , fungal parasite infection . Under systemic treatment corticosteroid immunosuppressive drug last 21 day start trial treatment . Participating another clinical trial pharmaceutical last six week start trial treatment . Not able understand information . Not willing able give write consent participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>BP-C1</keyword>
	<keyword>CDBPA</keyword>
	<keyword>Cis-coordinated complex platinum ( II ) polymer benzene polycarboxylic acid derive lignin</keyword>
	<keyword>Benzene polycarboxylic acid complex cis-diammineplatinum ( II )</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Platinum analogue</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cisplatin</keyword>
</DOC>